{"id":526407,"date":"2021-08-11T06:03:02","date_gmt":"2021-08-11T10:03:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/"},"modified":"2021-08-11T06:03:02","modified_gmt":"2021-08-11T10:03:02","slug":"second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/","title":{"rendered":"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study<\/b><\/p>\n<p class=\"bwalignc\">\nGrant proceeds support a patient preference information study of Orion subjects\n<\/p>\n<p>LOS ANGELES&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSecond Sight Medical Products, Inc. (NASDAQ: EYES) (the \u201cCompany\u201d or \u201cSecond Sight\u201d), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the Company better understand acceptable risks, necessary benefits, and appropriate risk\/benefit balance for visual cortical prostheses, from the perspective of the target population. The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study. The grant supplement is related to the $6.4 million NIH grant for the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant UH3NS103442. Second Sight reported promising two-year data from the Orion trial on May 12, 2021.\n<\/p>\n<p><b>About the Orion Visual Cortical Prosthesis System<\/b><\/p>\n<p>\nLeveraging Second Sight\u2019s 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brain\u2019s visual cortex, where it is intended to provide the perception of patterns of light. A six-subject early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.\n<\/p>\n<p><b>About Second Sight Medical Products, Inc.<\/b><\/p>\n<p>\nSecond Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Company\u2019s headquarters are in Los Angeles, California. More information is available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fsecondsight.com&amp;esheet=52475191&amp;newsitemid=20210811005213&amp;lan=en-US&amp;anchor=secondsight.com&amp;index=1&amp;md5=e4d50ec960bead7b2bc335761540eb60\">secondsight.com<\/a>.\n<\/p>\n<p><b>Safe Harbor<\/b><\/p>\n<p>\nThis press release contains certain \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d \u201cfuture,\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this press release regarding the amount of NIH grant proceeds expected to be received. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Second Sight\u2019s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) legal claims or proceedings relating to Second Sight\u2019s termination of the Memorandum of Understanding with Pixium Vision and costs relating thereto; (2) changes in applicable laws or regulations; (3) the possibility that Second Sight may be adversely affected by other economic, business, and\/or competitive factors; (4) the impact of COVID-19 on Second Sight\u2019s business; and (5) other risks and uncertainties indicated from time to time in Second Sight\u2019s Form 10-K for the year ended December 31, 2020, including those under \u201cRisk Factors\u201d therein, and in Second Sight\u2019s other filings with the SEC. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak and there may be additional risks that Second Sight considers immaterial or which are unknown. A further list and description of risks and uncertainties can be found in Second Sight\u2019s Annual Report on Form 10-K, filed on March 16, 2021, and as thereafter amended, and Form 10-Q filed May 13, 2021. Any forward-looking statement made by us in this press release is based only on information currently available to Second Sight and speaks only as of the date on which it is made. Second Sight undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210811005213\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210811005213\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations:<br \/>\n<\/b><br \/>Scott Dunbar<br \/>\n<br \/>Investor Relations:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@secondsight.com\">investors@secondsight.com<br \/>\n<\/a><br \/>(818) 833-5000\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> White House\/Federal Government Public Policy\/Government Health Medical Devices General Health Clinical Trials Optical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study Grant proceeds support a patient preference information study of Orion subjects LOS ANGELES&#8211;(BUSINESS WIRE)&#8211; Second Sight Medical Products, Inc. (NASDAQ: EYES) (the \u201cCompany\u201d or \u201cSecond Sight\u201d), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the Company better understand acceptable risks, necessary benefits, and appropriate risk\/benefit balance for visual cortical prostheses, from the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-526407","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study Grant proceeds support a patient preference information study of Orion subjects LOS ANGELES&#8211;(BUSINESS WIRE)&#8211; Second Sight Medical Products, Inc. (NASDAQ: EYES) (the \u201cCompany\u201d or \u201cSecond Sight\u201d), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the Company better understand acceptable risks, necessary benefits, and appropriate risk\/benefit balance for visual cortical prostheses, from the &hellip; Continue reading &quot;Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-11T10:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study\",\"datePublished\":\"2021-08-11T10:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/\"},\"wordCount\":900,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/\",\"name\":\"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-11T10:03:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/","og_locale":"en_US","og_type":"article","og_title":"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study - Market Newsdesk","og_description":"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study Grant proceeds support a patient preference information study of Orion subjects LOS ANGELES&#8211;(BUSINESS WIRE)&#8211; Second Sight Medical Products, Inc. (NASDAQ: EYES) (the \u201cCompany\u201d or \u201cSecond Sight\u201d), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses. The study will help the Company better understand acceptable risks, necessary benefits, and appropriate risk\/benefit balance for visual cortical prostheses, from the &hellip; Continue reading \"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-11T10:03:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study","datePublished":"2021-08-11T10:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/"},"wordCount":900,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/","name":"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-11T10:03:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210811005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/second-sight-medical-products-announces-a-new-nih-grant-supplement-for-its-orion-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=526407"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526407\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=526407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=526407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=526407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}